On the stock market since 2012, it operates in the world of health and science. It has 341 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $158.2M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 40% — still a thick cushion, though costs have been eating into it lately.
There is $490.9M in the vault; even if every debt were paid off, $158.2M would remain.
Over the last 12 months, company executives reported 32 buys and 11 sells. Management buying with its own money is usually read as a good sign.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, ICPT sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ICPT is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.